PSMA-targeting imaging agents
AssigneeThe Cleveland Clinic Foundation
InventorSteve Shih-lin Huang
Life of this patent
Estimating the term…
Abstract
A PSMA-specific agent comprising a compound according to Formula I or Formula II: wherein S1 is absent or is an organic spacer group comprising 3-10 carbons; A is an amino acid chain comprising 1 to 5 amino acids wherein at least one of the amino acids is selected from glutamic acid and aspartic acid; S2 is absent or is an organic spacer group comprising 1 to 15 carbons and/or 0 to 2 amino acids; I1 is an imaging group; and I2 is absent or is an imaging group. The PSMA-specific agents can be used to image PSMA within a tissue region and/or for the treatment of a cancer, such as prostate cancer.
Claims21
A PSMA-specific agent or pharmaceutically acceptable salt thereof comprising a compound according to Formula II,
- wherein S1 is an organic spacer group of formula
- A is an amino acid chain comprising 2-5 amino acids and wherein at least two amino acids are Glu;
- S2 is optionally present, and when present S2 is an organic spacer selected from an aryl group or one of the following groups:
- wherein n is from 3 to 5;
- I1 comprises DOTA;
- and I2 is either absent or comprises and imaging group selected from one of the following groups:
- wherein each of I1 and I2 optionally contain a radioisotope.
Dependencies are inferred from the claim text.